Frontiers in Cellular Neuroscience · 2014 · 173 citations · 50 references
Life SciencesNeurologyNeuroscienceGene ExpressionMolecular NeurobiologyNeurodegenerationMicrorna BiologyMultiple System AtrophyNeurodegenerative DiseasesNeurodegenerative DisordersParkinson DiseaseParkinsonian DisordersBiomarkers Of Parkinsonian DisordersCirculating MicrornasCirculating Rna BiomarkersDifferential Expression In MicrornaMicrorna BiomarkersParkinson Disease BiomarkersPost-transcriptional Gene RegulationPost-transcriptional Regulation
BACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative disorder which may be misdiagnosed with atypical conditions such as Multiple System Atrophy (MSA), due to overlapping clinical features. MicroRNAs (miRNAs) are small non-coding RNAs with a key role in post-transcriptional gene regulation. We hypothesized that identification of a distinct set of circulating miRNAs (cmiRNAs) could distinguish patients affected by PD from MSA and healthy individuals. Results. Using TaqMan Low Density Array technology, we analyzed 754 miRNAs and found 9 cmiRNAs differentially expressed in PD and MSA patients compared to healthy controls. We also validated a set of 4 differentially expressed cmiRNAs in PD and MSA patients vs. controls. More specifically, miR-339-5p was downregulated, whereas miR-223(*), miR-324-3p, and mir-24 were upregulated in both diseases. We found cmiRNAs specifically deregulated in PD (downregulation of miR-30c and miR-148b) and in MSA (upregulation of miR-148b). Finally, comparing MSA and PD, we identified 3 upregulated cmiRNAs in MSA serum (miR-24, miR-34b, miR-148b). Conclusions. Our results suggest that cmiRNA signatures discriminate PD from MSA patients and healthy controls and may be considered specific, non-invasive biomarkers for differential diagnosis.
50
Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 86.9K citations
Margaret M. Hoehn, Melvin D. Yahr · Neurology · 1967 · 12K citations · Full text